Development of 1,2,4-Oxadiazole Antimicrobial Agents to Treat Enteric Pathogens within the Gastrointestinal Tract
Noel P. Pitcher,
Jitendra R. Harjani,
Yichao Zhao,
Jianwen Jin,
Daniel R. Knight,
Lucy Li,
Papanin Putsathit,
Thomas V. Riley,
Glen P. Carter,
Jonathan B. Baell
Affiliations
Noel P. Pitcher
Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
Jitendra R. Harjani
Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
Yichao Zhao
Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
Jianwen Jin
Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
Daniel R. Knight
School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia
Lucy Li
Department of Microbiology & Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia
Papanin Putsathit
School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia
Thomas V. Riley
School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia
Glen P. Carter
Department of Microbiology & Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia
Jonathan B. Baell
School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing, People’s Republic of China
